Stage III Verrucous Carcinoma of the Larynx Terminated Phase 1 Trials for Cetuximab (DB00002)

IndicationStatusPhase
DBCOND0029516 (Stage III Verrucous Carcinoma of the Larynx)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00906360Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and NeckTreatment